130.65MMarket Cap-1.08P/E (TTM)
3.3200High3.2000Low495.11KVolume3.2600Open3.2500Pre Close1.62MTurnover2.64%Turnover RatioLossP/E (Static)39.95MShares15.050052wk High0.78P/B61.26MFloat Cap3.030052wk Low--Dividend TTM18.73MShs Float822.6000Historical High--Div YieldTTM3.69%Amplitude1.8100Historical Low3.2620Avg Price1Lot Size
Solid Biosciences Stock Forum
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
Wednesday, 15th January at 4:05 pm
- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 -
- FA: First-in-human clinical study of SGT-212 utilizing a dual route of ...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release
7. Remember, some stocks may get pumped WITHOUT any catalyst
8. NEVER be a blind follower.
LASTLY, If y...
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia
Tuesday, 7th January at 4:15 pm
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia -
- Dual route of administration enables direct delivery of AAV-based gene therapy to the cerebellum and...
RA capital and perspective advisors are both investors here. They also are invested in $Bright Minds Biosciences (DRUG.US)$
DRUG ran recently as we all know but also ran 3000% in 2022. Each time RA Capital and perspective advisors were invested and both times there were private placements after they ran.
In 2021 SLDB ran 450%, RA Capital and perspective advisors both invested and a private placement after it ran.
SLDB has not had a major run since but maybe it will a...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$